SCHEMBL939340

SCHEMBL939340

CN(Cc1nc2cccc(C(=O)N3CCC4(CC3)CCN(c3ccncc3)CC4)c2[nH]1)C(=O)c1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 10/20 0.45
CYP2C19 P33261 6/20 0.45
CYP3A4 P08684 9/20 0.45
CYP2D6 P10635 10/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
CYP1A2 P05177 6/20 0.43
TSHR P16473 7/20 0.42
HIF1A Q16665 5/20 0.42
ALDH1A1 P00352 5/20 0.42
USP2 O75604 2/20 0.42
BDKRB1 P46663 1/20 0.42
MAPK1 P28482 2/20 0.41
HPGD P15428 1/20 0.40
ITGB3 P05106 3/20 0.38
ITGA2B P08514 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938493 0.95 CYP2C19 (0.42) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL939674 0.89 CYP3A4 (0.42) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL940108 0.88 CYP2C9 (0.43) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL938301 0.85 ITGB3 (0.40) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL939306 0.84 CYP3A4 (0.40) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL938797 0.84 CYP2D6 (0.48) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL940790 0.83 PLD1 (0.37) ALDH1A1
SCHEMBL938222 0.81 CYP3A4 (0.39) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL939921 0.81 CYP2C9 (0.40) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2
SCHEMBL11947923 0.81 CYP3A4 (0.40) CYP2C9CYP2C19CYP3A4CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP claimed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US claimed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US claimed
EP-2440542-B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2013-12-18 EP disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US disclosed
WO-2010142402-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles BDKRB1, BDKRB2, BRD1 CYP2C9 362/4885CYP2C19 247/4885CYP3A4 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.